FDA Adds Boxed Warning to Labeling for Ferric Carboxymaltose Injection (Injectafer) to Describe Risk of Low Phosphate Levels
The FDA has added a Boxed Warning to the labeling for Ferric Carboxymaltose Injection (Injectafer) to describe the risk of developing clinically significant low phosphate levels in the blood.
The manufacturer of Injectafer, healthcare professionals prescribing iron replacement therapies, and regulatory/clinical teams responsible for monitoring drug safety profiles.
A Boxed Warning is the FDA’s most serious safety notification, suggesting that the risk of hypophosphatemia is significant enough to require prominent disclosure to prescribers. This update likely necessitates immediate changes to marketing materials, physician communications (DHCP letters), and internal risk management strategies to ensure adequate monitoring of patient electrolyte levels.
Regulatory and labeling teams should immediately update product inserts and promotional materials to reflect the Boxed Warning. Clinical teams and pharmacovigilance departments should review monitoring protocols for patient serum phosphate levels and update safety reporting databases to capture related adverse events specifically.
FDA Drug Safety Communication: FDA Adds Boxed Warning to Labeling for Ferric Carboxymaltose Injection (Injectafer) to Describe Risk of Low Phosphate Levels. Source: https://www.fda.gov/drugs/drug-safety-communications/fda-adds-boxed-warning-labeling-ferric-carboxymaltose-injection-injectafer-describe-risk-low
Open in openFDA / FDA.gov